Table 2.
Associations of 25 candidate SNPs with percentage decrease in FPG after 8-week gliclazide treatment in type 2 diabetic patients of cohort 1
| Gene | Encoded protein | SNP | Codon | Amino acid change | Minor allele frequency | Association with FPG decrease (P)* |
|---|---|---|---|---|---|---|
| ABCC8 | Sulfonylurea receptor (SUR1) | rs757110 | 1,369 | Ser→Ala | 0.432 | 0.002 |
| rs1799854 | — | — | 0.416 | 0.498 | ||
| rs2074312 | — | — | 0.500 | 0.031 | ||
| rs2237984 | — | — | 0.369 | 0.616 | ||
| rs2237981 | — | — | 0.256 | 0.046 | ||
| Kir6.2 (KCNJ11) | ATP-sensitive potassium channel, Kir6.2 | rs5210 | — | — | 0.480 | 0.002 |
| ENSA | Endosulfine alpha | rs7517 | — | — | 0.222 | 0.085 |
| PPARG | Peroxisome proliferative activated receptor γ | rs2972164 | — | — | 0.084 | 0.284 |
| rs10510412 | — | — | 0.346 | 0.480 | ||
| rs2959273 | — | — | 0.412 | 0.332 | ||
| CAPN10 | Calpain 10 | rs10933620 | — | — | 0.342 | 0.462 |
| rs3792267 | — | — | 0.107 | 0.765 | ||
| rs2975760 | — | — | 0.106 | 0.958 | ||
| TCF1 | Hepatocyte nuclear factor 1α | rs2464195 | — | — | 0.498 | 0.490 |
| rs1169300 | — | — | 0.499 | 0.457 | ||
| IRS1 | Insulin receptor substrate 1 | rs1801278 | 972 | Gly→Arg | 0.009 | 0.905 |
| rs9653366 | — | — | 0.189 | 0.065 | ||
| rs10498210 | — | — | 0.073 | 0.336 | ||
| rs12052364 | — | — | 0.172 | 0.039 | ||
| GLP1R | Glucagon-like peptide 1 receptor | rs1042044 | 260 | Phe→Leu | 0.492 | 0.496 |
| UCP2 | Uncoupling protein 2 | rs660339 | 55 | Val→Ala | 0.467 | 0.739 |
| PPARGC1A | Peroxisome proliferative activated receptor γ, coactivator 1α | rs8192678 | 482 | Ser→Gly | 0.425 | 0.596 |
| rs3736265 | 612 | Thr→Met | 0.175 | 0.780 | ||
| ADRB2 | β2-Adrenergic receptor | rs1042713 | 16 | Arg→Gly | 0.422 | 0.386 |
| rs1042714 | 27 | Gln→Glu | 0.099 | 0.897 |
*
Linear regression under additive model with adjustment for age, sex, total gliclazide dose, baseline HOMA-B, and HOMA-IR.